These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 10213228

  • 21. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM, Narita Y, Furnari FB, Gan HK, Murone C, Ahlkvist M, Luwor RB, Burgess AW, Stockert E, Jungbluth AA, Old LJ, Cavenee WK, Scott AM, Johns TG.
    Clin Cancer Res; 2005 Sep 01; 11(17):6390-9. PubMed ID: 16144944
    [Abstract] [Full Text] [Related]

  • 22. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
    Overholser JP, Prewett MC, Hooper AT, Waksal HW, Hicklin DJ.
    Cancer; 2000 Jul 01; 89(1):74-82. PubMed ID: 10897003
    [Abstract] [Full Text] [Related]

  • 23. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, Bianco AR, Agrawal S, Ciardiello F, Tortora G.
    Clin Cancer Res; 2006 Jan 15; 12(2):577-83. PubMed ID: 16428503
    [Abstract] [Full Text] [Related]

  • 24. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.
    Fan Z, Baselga J, Masui H, Mendelsohn J.
    Cancer Res; 1993 Oct 01; 53(19):4637-42. PubMed ID: 8402640
    [Abstract] [Full Text] [Related]

  • 25. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.
    Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L.
    Int J Radiat Oncol Biol Phys; 2004 Jul 15; 59(4):1163-73. PubMed ID: 15234052
    [Abstract] [Full Text] [Related]

  • 26. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A.
    Cancer Res; 1999 Mar 15; 59(6):1236-43. PubMed ID: 10096554
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
    Krause M, Schütze C, Petersen C, Pimentel N, Hessel F, Harstrick A, Baumann M.
    Radiother Oncol; 2005 Feb 15; 74(2):109-15. PubMed ID: 15734198
    [Abstract] [Full Text] [Related]

  • 29. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4291-9. PubMed ID: 17634559
    [Abstract] [Full Text] [Related]

  • 30. The epidermal growth factor receptor as a target for cancer therapy.
    Mendelsohn J.
    Endocr Relat Cancer; 2001 Mar 15; 8(1):3-9. PubMed ID: 11350723
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation.
    Wang H, Shi B, Zhang Q, Jiang H, Hu S, Kong J, Yao M, Yang S, Li Z.
    FASEB J; 2012 Jan 15; 26(1):73-80. PubMed ID: 21917986
    [Abstract] [Full Text] [Related]

  • 33. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
    Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y, Witte L, Berry S, Moore M, Kerbel RS.
    Clin Cancer Res; 2009 Apr 01; 15(7):2397-405. PubMed ID: 19276250
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 36. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ.
    Clin Cancer Res; 2002 May 15; 8(5):994-1003. PubMed ID: 12006511
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
    Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z.
    Clin Cancer Res; 2000 Feb 15; 6(2):701-8. PubMed ID: 10690556
    [Abstract] [Full Text] [Related]

  • 39. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
    Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Tortora G.
    J Natl Cancer Inst; 1998 Jul 15; 90(14):1087-94. PubMed ID: 9672257
    [Abstract] [Full Text] [Related]

  • 40. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H.
    Cancer Lett; 2010 Jun 01; 292(1):54-63. PubMed ID: 19959278
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.